Dr. Eric Leire, MD, MBA, Chief Executive Officer: brings to the Company a solid biotechnology expertise through his experience in the pharmaceutical industry (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of several private and public biotech companies such as APT Therapeutics, Paringenix), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).   He is the inventor of several patents.

He also serves on the board of several biotechnology companies such as Pherecydes (ALPH.PA), Inhatarget, Immunethep, BSIM Therapeutics.  Furthermore, Eric has been CEO of several Cell & gene therapy companies such as Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB: DDRT).  He has  also served as Non-Executive Director on the board of several cell & gene therapy companies such as Genizon (Canada) or FIT Biotechnology (Finland).  He holds an MD from Grenoble University and an MBA from HEC, Paris and Kellogg, Northwestern University. He also sits on the board of OSE Immunotherapeutics.